A promising approach to improving the treatment of brain tumors is the
targeted delivery of drugs, which offers opportunities to increase drug efficacy while
reducing systemic toxicity. This abstract provides an overview of the advantages and
disadvantages of targeted medication delivery for brain tumors. Opportunities include
minimising side effects by reducing systemic exposure, improving efficacy by
accurately delivering therapeutic drugs to the tumor site, as well as being able to pass
across the blood-brain barrier (BBB) to reach the brain tumor. Additionally,
combination therapy approaches, and personalized medicine approaches catered to the
molecular features of particular tumours are made possible by targeted drug delivery.
To fully achieve the potential of targeted drug delivery against brain tumours, some
challenges must be overcome. The complex nature and diversity of brain tumours, the
BBB's impenetrable barrier, the development of resistance to targeted therapy, and the
conversion of preclinical research into clinically effective treatments are some of these
difficulties. Collaboration between researchers, physicians, engineers, and regulatory
authorities will be necessary to address these issues. To improve the field of targeted
drug delivery against brain tumours, novel approaches are required to target specific
molecular pathways, get over the blood-brain barrier, and overcome drug resistance
mechanisms. In conclusion, targeted drug delivery has great promise for improving
patient outcomes and revolutionising the treatment of brain tumours with more research
and development.
Keywords: Brain tumor, Blood-brain barrier, Targeted drug delivery.
